Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandra Leary

Showing results (51-60 of 217) with videos related to

Pageof 22
Sort By:
Laboratory Investigation; a Journal of Technical Methods and Pathology|October 12, 2025
Assessing the Status of Cyclin E1 (CCNE1) From Gene to Protein Level in Ovarian and Endometrial Carcinomas: A Systematic ReviewAlexis Trecourt, Catherine Genestie, Alexander Valent, et al.
Bulletin Du Cancer|October 11, 2021
[Surgical de-escalation in gynecologic oncology]François Zaccarini, Claire Sanson, Amandine Maulard, et al.
JNCI Cancer Spectrum|June 30, 2020
Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7)Olivier Colomban, Michel Tod, Julien Peron, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 15, 2025
Prognosis of stage I ovarian mucinous tumors according to expansile and infiltrative typesMalek Bouhani, Stéphanie Schérier, Catherine Genestie, et al.
Bulletin Du Cancer|September 22, 2020
[Nice-Saint-Paul de Vence 2020 recommendations for clinical practice: Management of metastatic and/or relapsing endometrial cancer]Jérôme Alexandre, Marie Aude Le Frere-Belda, Karine Prulhiere, et al.
Gynecologic Oncology|November 14, 2013
Adjuvant platinum-based chemotherapy for borderline serous ovarian tumors with invasive implantsAlexandra Leary, Marie Christina Petrella, Patricia Pautier, et al.
The American Journal of Surgical Pathology|August 2, 2024
Additional Considerations on Aberrant BRG1 (SMARCA4) Expression in Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT)Joanna Cyrta, Riwan Brillet, Enora Laas, et al.
Investigational New Drugs|December 15, 2018
Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancerAlexandra Leary, Christophe Le Tourneau, Andrea Varga, et al.
Cancer Chemotherapy and Pharmacology|December 24, 2008
A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapyAlexandra Leary, L Assersohn, D Cunningham, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 22, 2018
Characteristics and Prognosis of Stage I Ovarian Mucinous Tumors According to Expansile or Infiltrative TypeSebastien Gouy, Marine Saidani, Amandine Maulard, et al.
Pageof 22

Showing results (51-60 of 217) with videos related to

Sort By:
Pageof 22
Laboratory Investigation; a Journal of Technical Methods and Pathology|October 12, 2025
Assessing the Status of Cyclin E1 (CCNE1) From Gene to Protein Level in Ovarian and Endometrial Carcinomas: A Systematic ReviewAlexis Trecourt, Catherine Genestie, Alexander Valent, et al.
Bulletin Du Cancer|October 11, 2021
[Surgical de-escalation in gynecologic oncology]François Zaccarini, Claire Sanson, Amandine Maulard, et al.
JNCI Cancer Spectrum|June 30, 2020
Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7)Olivier Colomban, Michel Tod, Julien Peron, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 15, 2025
Prognosis of stage I ovarian mucinous tumors according to expansile and infiltrative typesMalek Bouhani, Stéphanie Schérier, Catherine Genestie, et al.
Bulletin Du Cancer|September 22, 2020
[Nice-Saint-Paul de Vence 2020 recommendations for clinical practice: Management of metastatic and/or relapsing endometrial cancer]Jérôme Alexandre, Marie Aude Le Frere-Belda, Karine Prulhiere, et al.
Gynecologic Oncology|November 14, 2013
Adjuvant platinum-based chemotherapy for borderline serous ovarian tumors with invasive implantsAlexandra Leary, Marie Christina Petrella, Patricia Pautier, et al.
The American Journal of Surgical Pathology|August 2, 2024
Additional Considerations on Aberrant BRG1 (SMARCA4) Expression in Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT)Joanna Cyrta, Riwan Brillet, Enora Laas, et al.
Investigational New Drugs|December 15, 2018
Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancerAlexandra Leary, Christophe Le Tourneau, Andrea Varga, et al.
Cancer Chemotherapy and Pharmacology|December 24, 2008
A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapyAlexandra Leary, L Assersohn, D Cunningham, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 22, 2018
Characteristics and Prognosis of Stage I Ovarian Mucinous Tumors According to Expansile or Infiltrative TypeSebastien Gouy, Marine Saidani, Amandine Maulard, et al.
Pageof 22